<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cosyntropin (tetracosactide): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cosyntropin (tetracosactide): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cosyntropin (tetracosactide): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9298" href="/d/html/9298.html" rel="external">see "Cosyntropin (tetracosactide): Drug information"</a> and <a class="drug drug_patient" data-topicid="91661" href="/d/html/91661.html" rel="external">see "Cosyntropin (tetracosactide): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F154800"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cortrosyn</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866452"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Cortrosyn;</li>
<li>Synacthen Depot</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1051966"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenal Corticosteroid</span>;</li>
<li>
<span class="list-set-name">Diagnostic Agent, Adrenocortical Insufficiency</span></li></ul></div>
<div class="block don drugH1Div" id="F53462413"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Dosing units may vary (ie, mcg, mcg/<b>kg</b>, or mcg/<b>m<sup>2</sup></b>); use extra caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ba4e708-e276-49ec-86da-e24a0556b380">Adrenocortical insufficiency, diagnostic test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenocortical insufficiency, diagnostic test (ACTH stimulation test):</b> Limited data available in preterm neonates; dosing regimens variable; refer to institutional protocols. <b>Note:</b> The Endocrine Society practice guideline recommends the standard dose for diagnosing primary adrenal insufficiency and suggests that the low dose be used for diagnosing primary adrenal insufficiency only when cosyntropin is in short supply. Some doses, particularly the low dose, may require additional dilution; use extra caution to reduce dosing and administration issues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Standard-dose ACTH stimulation test</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Weight-directed dosing: Neonates: IV: 15 mcg/<b>kg</b>/dose once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Fixed dosing: Neonates: IM, IV: 125 mcg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Low-dose ACTH stimulation test</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Preterm neonates: IV: 1 mcg/<b>kg</b>/dose once; reported range: 0.1 to 3.5 mcg/<b>kg</b>/dose; maximum dose: 1 mcg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10393606','lexi-content-ref-8636825','lexi-content-ref-32901267','lexi-content-ref-16159938']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10393606','lexi-content-ref-8636825','lexi-content-ref-32901267','lexi-content-ref-16159938'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Term neonates: IV: 1 mcg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27779350','lexi-content-ref-26760044','lexi-content-ref-25901540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27779350','lexi-content-ref-26760044','lexi-content-ref-25901540'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="307fae68-e606-4993-bf0f-80ccf7b67216">Congenital adrenal hyperplasia, confirmatory evaluation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital adrenal hyperplasia, confirmatory evaluation:</b>
<b>Note:</b> Testing should be deferred until 24 to 48 hours of life to avoid inaccurate results (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30272171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Very low-birth-weight neonates (eg, &lt;1,500 g): IV: 125 to 250 mcg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30272171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: IV: 250 mcg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30272171'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F154818"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing units may vary (ie, mcg, mcg/<b>kg,</b> or mcg/<b>m<sup>2</sup></b>); use extra caution.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ba4e708-e276-49ec-86da-e24a0556b380">Adrenocortical insufficiency, diagnostic test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenocortical insufficiency, diagnostic test (ACTH stimulation test): Note: </b>The Endocrine Society practice guideline recommends the standard dose for diagnosing primary adrenal insufficiency and suggests that the low dose be used only when cosyntropin is in short supply (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044'])">Ref</a></span>). Refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Standard-dose ACTH stimulation test: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 15 mcg/<b>kg/</b>dose once; maximum dose: 125 mcg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;2 years: IM, IV: 125 mcg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥2 years and Adolescents: IM, IV: 250 mcg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044','lexi-content-ref-Manu.1'])">Ref</a></span>). When greater cortisol stimulation is needed, an IV infusion may be used: 250 mcg administered over 6 hours (rate: 40 mcg/hour) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Low-dose ACTH stimulation test: </i>Limited data available: <b>Note:</b> Low doses require additional dilutions; use extra caution to reduce dosing issues (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: IV: 1 mcg once or 1 mcg/<b>m<sup>2</sup></b>/dose once; maximum dose: 1 mcg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20626639','lexi-content-ref-26760044','lexi-content-ref-18697868','lexi-content-ref-19955760','lexi-content-ref-17849739','lexi-content-ref-10681636']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20626639','lexi-content-ref-26760044','lexi-content-ref-18697868','lexi-content-ref-19955760','lexi-content-ref-17849739','lexi-content-ref-10681636'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="307fae68-e606-4993-bf0f-80ccf7b67216">Congenital adrenal hyperplasia, confirmatory evaluation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Congenital adrenal hyperplasia, confirmatory evaluation:</b> Limited data available: Infants and Children: IV: 250 mcg once (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30272171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30272171'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>
<span style="text-decoration: underline">Canadian labeling</span>: </b></i>Synacthen Depot [Canadian product]: <b>Note:</b> Canadian product is for IM administration and dosing is presented in mg; since product is a depot formulation, standard dose equivalencies are not accurate and dose must be individualized.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6ba4e708-e276-49ec-86da-e24a0556b380">Adrenocortical insufficiency, diagnostic test</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adrenocortical insufficiency, diagnostic test (ACTH stimulation test):</b> Synacthen Depot [Canadian product]:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: IM: 1 mg administered as a single dose or once daily for 3 or 4 days (depending on method of testing; refer to manufacturer's labeling for detailed information). <b>Note:</b> For patients with severe adrenal insufficiency, some clinicians administer dexamethasone on days that cosyntropin is administered to provide steroid coverage.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a6608b3-fd67-4c09-a374-bc417c0679c2">Anti-inflammatory or immunosuppressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-inflammatory or immunosuppressive: Note:</b> Titrate to lowest effective dose at the longest effective dosing interval. Synacthen Depot [Canadian product]:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 3 to ≤6 years: IM: Initial: 0.25 to 0.5 mg daily for ~3 days; maintenance: 0.25 to 0.5 mg every 2 to 8 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents ≤15 years: IM: Initial: 0.25 to 1 mg daily for ~3 days; maintenance: 0.25 to 1 mg every 2 to 8 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥16 years: IM: Initial for acute treatment: 1 mg daily for 3 days; maintenance dose: 0.5 to 1 mg every 2 to 3 days or twice weekly <b>or</b> 2 mg once weekly or less frequently.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Transferring from corticosteroids:</i> Synacthen Depot [Canadian product]: Children ≥3 years and Adolescents: IM: Initial: 1 mg daily; gradually reduce steroid by 25% of original dose on successive days. Upon withdrawal from steroid, adjust cosyntropin depot dose as needed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Transferring from animal-derived ACTH:</i> Synacthen Depot [Canadian product]: Children ≥3 years and Adolescents: Conversion varies depending on product previously used. Manufacturer suggests that patients previously receiving ACTH gel 40 units daily should receive cosyntropin depot 0.5 mg every other day; adjust dose based on response, preferably by extending the dosing interval.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090024"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51090025"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doa drugH1Div" id="F154802"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9298" href="/d/html/9298.html" rel="external">see "Cosyntropin (tetracosactide): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e0165884-ee26-4f76-b43f-16eacd0f12d0">Diagnostic use</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic use: Screening of adrenocortical insufficiency:</b>
<b>IM, IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Conventional dose:</i> 0.25 mg; <b>Note:</b> Doses in the range of 0.25 to 0.75 mg have been used in clinical studies; however, maximal response is seen with 0.25 mg dose. When greater cortisol stimulation is needed, an IV infusion may be used: 0.25 mg administered at 0.04 mg/hour over 6 hours</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Low-dose protocol (off-label dose):</i> 1 mcg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10084558']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10084558'])">Ref</a></span>); <b>Note:</b> The use of the low-dose protocol has been advocated by some clinicians, particularly in mild or secondary adrenal insufficiency. The low-dose protocol is not recommended in critically ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18496365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18496365'])">Ref</a></span>). The Endocrine Society practice guideline recommends the conventional dose (ie, 0.25 mg) for diagnosing primary adrenal insufficiency and suggests that the low-dose be used only when cosyntropin is in short supply (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26760044']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26760044'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Synacthen Depot [Canadian product]: IM: 1 mg administered as a single dose or once daily for 3 or 4 days (depending on method of testing; refer to manufacturer labeling for detailed information). <b>Note:</b> For patients with severe adrenal insufficiency, some clinicians administer dexamethasone on days that Synacthen Depot is administered to provide steroid coverage.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Diagnostic use: Adrenal vein sampling (AVS) in primary aldosteronism (off-</b>
<b>label use): </b> IV: 50 <b>mcg</b>/hour continuous infusion started 30 minutes prior to adrenal vein catheterization and continued until procedure completion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15657580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15657580'])">Ref</a></span>). Alternatively, may consider a 250 <b>mcg</b> bolus dose (with AVS performed prior to and after the bolus dose); however, some studies suggest that bolus administration followed by simultaneous AVS may fail to enhance the diagnostic accuracy of AVS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26918291','lexi-content-ref-26934393','lexi-content-ref-16508586','lexi-content-ref-18398342']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26918291','lexi-content-ref-26934393','lexi-content-ref-16508586','lexi-content-ref-18398342'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a702497-5e02-4820-a3ea-4ad6ba709314">Therapeutic use</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Therapeutic use:</b> Synacthen Depot [Canadian product]: <b>IM</b> (<b>Note:</b> Titrate to lowest effective dose at the longest effective dosing interval): Initial for acute treatment: 1 mg daily for 3 days; maintenance dose is individualized: 0.5 to 1 mg every 2 to 3 days or twice weekly or 2 mg once weekly or less frequently</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transferring from corticosteroids:</b> Synacthen Depot [Canadian product]: IM: Initial: 1 mg daily; gradually reduce steroid by 25% of original dose on successive days. Upon withdrawal from steroid adjust Synacthen Depot dose as needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Transferring from animal-derived ACTH:</b> Synacthen Depot [Canadian product]: IM: Conversion varies depending on product previously used. Manufacturer suggests that patients previously receiving ACTH gel 40 units daily should receive Synacthen Depot 0.5 mg every other day; adjust dose based on response, preferably by extending the dosing interval.</p></div>
<div class="block dora drugH1Div" id="F50992056"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50989363"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F154779"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined. Adverse events associated with other corticosteroids may be observed when Synacthen Depot (Canadian product) is used for therapeutic purposes. Refer to corticosteroid monographs for comprehensive lists.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Bradycardia, hypertension, peripheral edema, tachycardia</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash, urticaria at injection site (with erythema)</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Adrenal hemorrhage (Synacthen Depot)</p></div>
<div class="block coi drugH1Div" id="F154791"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to cosyntropin or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">Synacthen Depot [Canadian product]: Additional contraindications: Treatment of asthma or other allergic conditions (increased risk of anaphylactic reactions); use in premature babies and neonates &lt;1 month; acute psychosis; untreated bacterial, fungal, and viral infections; active or latent peptic ulcer; refractory heart failure; Cushing syndrome; treatment of primary adrenocortical insufficiency; adrenogenital syndrome</p></div>
<div class="block war drugH1Div" id="F154776"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Corticotropin allergy: Cortrosyn: Use with caution in patients with a history of allergic reactions to corticotropin or preexisting allergic disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Synacthen Depot [Canadian product]: Hypersensitivity reactions (including severe reactions) may occur particularly in patients with asthma or other allergies and often within 30 minutes of administration; monitor for hypersensitivity for ~1 hour after administration. Prolonged use may increase the risk of allergic reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Synacthen Depot [Canadian product]: Use caution in patients with hypertension or thromboembolic disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastrointestinal disease: Synacthen Depot [Canadian product]: Use caution in patients with nonspecific ulcerative colitis, diverticulitis, or recent intestinal anastomosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic disease: Synacthen Depot [Canadian product]: Enhanced effects may be observed in patients with cirrhosis of the liver.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infections: Synacthen Depot [Canadian product]: Use caution in patients with acute or chronic infections (especially varicella or vaccinia) or exanthematous and fungal diseases. Use with caution in patients with tuberculosis (TB) infection (latent TB); treatment may reactivate TB infection. Rule out amebiasis prior to initiating therapy; may activate latent amebiasis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Use may cause transient worsening of myasthenia gravis (MG) (eg, within first 2 weeks of treatment); monitor for worsening MG (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Not recommended for the treatment of optic neuritis; may increase frequency of new episodes. Consider routine eye exams in chronic users.</p>
<p style="text-indent:-2em;margin-left:4em;">• Osteoporosis: Synacthen Depot [Canadian product]: Use caution in patients with osteoporosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Preexisting psychiatric conditions may be exacerbated by corticosteroid use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal disease: Synacthen Depot [Canadian product]: Use caution in patients with renal insufficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Synacthen Depot [Canadian product]: Enhanced effects may be observed with hypothyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage forms specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Synacthen Depot [Canadian product]: Contains benzyl alcohol; avoid use in infants and children &lt;3 years of age; contraindicated in neonates.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunizations: Synacthen Depot [Canadian product]: Live vaccines should not be given concurrently.</p>
<p style="text-indent:-2em;margin-left:4em;">• Inaccurate test result: Cortrosyn: False cortisol levels may occur with certain medications or disease states. Discontinue glucocorticoids and spironolactone the day of testing; long-acting glucocorticoids may need to be stopped earlier. Discontinue estrogen-containing medications 4 to 6 weeks prior to testing. Levels may be low in patients with cirrhosis or nephrotic syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery/trauma: Synacthen Depot [Canadian product]: Augmentation or resumption of therapy may be necessary in patients undergoing surgery or subjected to trauma either during or within 1 year of therapy discontinuation; adjunctive rapid acting corticosteroids may be necessary during periods of stress.</p></div>
<div class="block foc drugH1Div" id="F154785"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cortrosyn: 0.25 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F154772"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323079"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cortrosyn Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $127.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Cosyntropin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg (per each): $96.24</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866453"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cortrosyn: 0.25 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension, Intramuscular: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Synacthen Depot: 1 mg/mL (1 mL) [contains benzyl alcohol]</p></div>
<div class="block adip drugH1Div" id="F53565889"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">250 mcg of cosyntropin results in a similar amount of adrenal cortex stimulation as 25 units of natural corticotropin.</p></div>
<div class="block admp drugH1Div" id="F52612459"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM:</p>
<p style="text-indent:-2em;margin-left:4em;">Cortrosyn: Reconstituted powder for injection only: Administer as 0.25 mg/mL (250 <b>mcg/</b>mL) concentration.</p>
<p style="text-indent:-2em;margin-left:4em;">Synacthen Depot [Canadian product]: Shake ampule until uniform appearance; administer by deep IM injection. Self-administration by patient is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Reconstituted powder for injection only. <b>Note: </b>Synacthen Depot [Canadian product] should <b>not</b> be administered IV.</p>
<p style="text-indent:-2em;margin-left:4em;">IV push: Administer over 2 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion: Infuse over 6 hours (~40 <b>mcg</b>/hour).</p></div>
<div class="block adm drugH1Div" id="F154788"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: May administer by IV injection over 2 minutes or as an IV infusion over 4 to 8 hours. Synacthen Depot [Canadian product] should <b>not</b> be administered IV.</p>
<p style="text-indent:-2em;margin-left:4em;">Adrenal vein sampling (off-label): Administer as continuous infusion beginning 30 minutes before adrenal vein catheterization and continue throughout the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26934393','lexi-content-ref-15657580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26934393','lexi-content-ref-15657580'])">Ref</a></span>). Alternatively, a bolus regimen has been studied that requires a baseline AVS followed by bolus cosyntropin followed by repeat AVS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26918291','lexi-content-ref-26934393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26918291','lexi-content-ref-26934393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">IM: May administer IM.</p>
<p style="text-indent:-2em;margin-left:2em;">Synacthen Depot [Canadian product]: Shake ampule until uniform appearance; administer by IM injection in the buttocks. Self-administration by patient is not recommended.</p></div>
<div class="block sts drugH1Div" id="F154797"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Powder for injection: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). After dilution for IV infusion, stable for 12 hours at room temperature.</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension for injection: Synacthen Depot [Canadian product]: Store refrigerated between 2°C to 8°C (36°F to 46°F). Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53566259"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Diagnostic test to differentiate primary adrenal from secondary (pituitary) adrenocortical insufficiency (FDA approved in pediatric patients [age not specified] and adults); has also been used in the diagnosis of congenital adrenal hyperplasia.</p></div>
<div class="block mst drugH1Div" id="F154837"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cortrosyn may be confused with colchicine, corticorelin, corticotropin, Cotazym</p>
<p style="text-indent:-2em;margin-left:4em;">Cosyntropin may be confused with corticorelin, corticotropin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299097"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6219534"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">ClonazePAM: Cosyntropin may enhance the hepatotoxic effect of ClonazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Orally Inhaled): May diminish the diagnostic effect of Cosyntropin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the diagnostic effect of Cosyntropin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cortisone: May diminish the diagnostic effect of Cosyntropin. Management: Patients receiving cortisone should omit their pre-test dose on the day selected for cosyntropin testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: Cosyntropin may enhance the hepatotoxic effect of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May diminish the diagnostic effect of Cosyntropin. Management: Discontinue estrogen containing drugs 4 to 6 weeks prior to cosyntropin (ACTH) testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): May diminish the diagnostic effect of Cosyntropin. Management: Patients receiving hydrocortisone should omit their pre-test dose on the day selected for cosyntropin testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrazepam: Cosyntropin may enhance the hepatotoxic effect of Nitrazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: Cosyntropin may enhance the hepatotoxic effect of PHENobarbital. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Cosyntropin may enhance the hepatotoxic effect of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: Cosyntropin may enhance the hepatotoxic effect of Primidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May diminish the diagnostic effect of Cosyntropin. Management: Patients receiving spironolactone should omit their pre-test dose on the day selected for cosyntropin testing.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valproate Products: Cosyntropin may enhance the hepatotoxic effect of Valproate Products.  Management: Avoid concomitant use of Synacthen Depot (dosage form available in Canada) with valproic acid.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F13447516"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted with cosyntropin; adverse events have been observed with corticosteroids in animal reproduction studies. Some studies have shown an association between first trimester systemic corticosteroid use and oral clefts (Park-Wyllie 2000; Pradat 2003). Systemic corticosteroids may also influence fetal growth (decreased birth weight); however, information is conflicting (Lunghi 2010). When systemic corticosteroids are needed in pregnancy, it is generally recommended to use the lowest effective dose for the shortest duration of time, avoiding high doses during the first trimester (Leachman 2006; Lunghi 2010; Makol 2011; Østensen 2009). Cosyntropin is the recommended test to diagnose primary adrenal insufficiency during pregnancy. Pregnancy may alter cortisol levels, and higher concentrations are used to interpret the results based on trimester (Bornstein 2016).</p></div>
<div class="block mopp drugH1Div" id="F57147238"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Plasma cortisol concentration(s) as appropriate for specific test strategy.</p>
<p style="text-indent:-2em;margin-left:2em;">Synacthen Depot [Canadian product]: Observe patient for ~1 hour after administration for signs/symptoms of hypersensitivity; with prolonged use monitor blood pressure, weight, urinalysis, glucose, electrolytes, signs and symptoms of infection, cataract formation, intraocular pressure, bone mass density and growth in children, ECG (in children).</p></div>
<div class="block rerp drugH1Div" id="F53565887"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Adrenocortical insufficiency, diagnostic test:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Response following standard dose: Peak cortisol concentration &lt;18 mcg/dL (SI: &lt;496.6 nmol/L) (assay dependent) at 30 or 60 minutes indicates adrenal insufficiency (ES [Bornstein 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">Synacthen Depot [Canadian product]:</p>
<p style="text-indent:-2em;margin-left:6em;">5-hour test: Plasma cortisol levels double in first hour then increase more gradually; normal values at 5 hours: 37 to 66 mcg/dL (SI: 1,020.8 to 1,820.9 nmol/L); 3-day test.</p>
<p style="text-indent:-2em;margin-left:6em;">3-day test: There are multiple procedure methods; see manufacturer's labeling for details.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Congenital adrenal hyperplasia (CAH), confirmatory evaluation:</i></p>
<p style="text-indent:-2em;margin-left:4em;">17-hydroxyprogesterone: &gt;1 mcg/dL 60 minutes after administration indicates CAH due to 21-hydroxylase deficiency (ES [Speiser 2018]).</p></div>
<div class="block pha drugH1Div" id="F154775"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates the adrenal cortex to secrete adrenal steroids (including hydrocortisone, cortisone), androgenic substances, and a small amount of aldosterone</p></div>
<div class="block phk drugH1Div" id="F154790"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IM, IV: Within 5 minutes increases in plasma cortisol concentrations are observed in healthy individuals</p>
<p style="text-indent:-2em;margin-left:2em;">Maximum effect: IM, IV: 45-60 minutes peak plasma cortisol concentration </p>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Synacthen Depot [Canadian product]: IM: Plasma concentrations of 200-300 pg/mL maintained for 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Synacthen Depot [Canadian product]: IM: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Synacthen Depot [Canadian product]: V<sub>d</sub>: ~43% of body weight</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Synacthen Depot [Canadian product]: 7 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM, IV push: ~1 hour; plasma cortisol levels rise in healthy individuals within 5 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038590"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Synacten</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cortrosina</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Synacthen Deposito</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adrenocortine | Cortrosyn</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nuvacthen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">S-cortrophine | Synacthen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Tetracosactide Dci</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn | Synacthen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn | Nuvacthen | Synacthene</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn | Synacthen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn | Cortrosyn z</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Nuvacthen | Synacten | Synacthen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Synacten</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Synacthen depot cd</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn | Synacthen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn | Cosyntropin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Synacthen Deposito</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Synacthen Depot</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Synacten | Synacthen depot</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Synachten</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cortrosyn</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Synacten</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Synacthen</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Synachten | Synacthen</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-10084558">
<a name="10084558"></a>Abdu TAM, Elhadd TA, Neary R, et al, “Comparison of the Low Dose Short Synacthen Test (1 μg), the Conventional Dose Short Synacthen Test (250 μg), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients With Pituitary Disease,” <i>J Clin Endocrinol Metab</i>, 1999, 84(3):838-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/10084558/pubmed" id="10084558" target="_blank">10084558</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28938253">
<a name="28938253"></a>Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. <i>Crit Care Med</i>. 2017;45(12):2078-2088. doi: 10.1097/CCM.0000000000002737.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/28938253/pubmed" id="28938253" target="_blank">28938253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12186604">
<a name="12186604"></a>Annane D, Sebille V, Charpentier C, et al, “Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,” <i>JAMA</i>, 2002, 288(7):862-71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/12186604/pubmed" id="12186604" target="_blank">12186604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26760044">
<a name="26760044"></a>Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(2):364-389. doi: 10.1210/jc.2015-1710.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/26760044/pubmed" id="26760044" target="_blank">26760044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7714095">
<a name="7714095"></a>Broide J, Soferman R, Kivity S, et al, “Low-Dose Adrenocorticotropin Test Reveals Impaired Adrenal Function in Patients Taking Inhaled Corticosteroids,” <i>J Clin Endocrinol Metab</i>, 1995, 80(4):1243-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/7714095/pubmed" id="7714095" target="_blank">7714095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20626639">
<a name="20626639"></a>Cemeroglu AP, Kleis L, Postellon DC, et al, "Comparison of Low-Dose and High-Dose Cosyntropin Stimulation Testing in Children," <i>Pediatr Int</i>, 2011, 53(2):175-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/20626639/pubmed" id="20626639" target="_blank">20626639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10393606">
<a name="10393606"></a>Cole CH, Shah B, Abbasi S, et al, "Adrenal Function in Premature Infants During Inhaled Beclomethasone Therapy," <i>J Pediatr</i>, 1999, 135(1):65-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/10393606/pubmed" id="10393606" target="_blank">10393606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cortrosyn.1">
<a name="Cortrosyn.1"></a>Cortrosyn (cosyntropin) [prescribing information]. Rancho Cucamonga, CA: Amphastar Pharmaceuticals Inc; December 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cortrosyn.1">
<a name="Cortrosyn.1"></a>Cortrosyn (cosyntropin) [prescribing information]. Rancho Cucamonga, CA: Amphastar Pharmaceuticals Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Cosyntropin [prescribing information]. Rockford, IL: Mylan Institutional LLC; January 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27779350">
<a name="27779350"></a>Crawford JH, Hull MS, Borasino S, et al. Adrenal insufficiency in neonates after cardiac surgery with cardiopulmonary bypass. <i>Paediatr Anaesth</i>. 2017;27(1):77-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/27779350/pubmed" id="27779350" target="_blank">27779350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26918291">
<a name="26918291"></a>El Ghorayeb N, Mazzuco TL, Bourdeau I, et al. Basal and post-ACTH aldosterone and its ratios are useful during adrenal vein sampling in primary aldosteronism. <i>J Clin Endocrinol Metab</i>. 2016;101(4):1826-1835. doi: 10.1210/jc.2015-3915.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/26918291/pubmed" id="26918291" target="_blank">26918291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18697868">
<a name="18697868"></a>Kazlauskaite R, Evans AT, Villabona CV, et al, "Corticotropin Tests for Hypothalamic-Pituitary-Adrenal Insufficiency: A Metaanalysis," <i>J Clin Endocrinol Metab</i>, 2008, 93(11):4245-53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/18697868/pubmed" id="18697868" target="_blank">18697868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19955760">
<a name="19955760"></a>Kazlauskaite R, Maghnie M. Pitfalls in the diagnosis of central adrenal insufficiency in children. <i>Endocr Dev</i>. 2010;17:96-107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/19955760/pubmed" id="19955760" target="_blank">19955760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8636825">
<a name="8636825"></a>Korte C, Styne D, Merritt TA, et al, "Adrenocortical Function in the Very Low Birth Weight Infant: Improved Testing Sensitivity and Association With Neonatal Outcome," <i>J Pediatr</i>, 1996, 128(2):257-63.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/8636825/pubmed" id="8636825" target="_blank">8636825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16677965">
<a name="16677965"></a>Leachman SA and Reed BR, "The Use of Dermatologic Drugs in Pregnancy and Lactation," <i>Dermatol Clin</i>, 2006, 24(2):167-97, vi.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/16677965/pubmed" id="16677965" target="_blank">16677965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32901267">
<a name="32901267"></a>LeDrew R, Bariciak E, Webster R, Barrowman N, Ahmet A. Evaluating the low-dose ACTH stimulation test in neonates: ideal times for cortisol measurement. <i>J Clin Endocrinol Metab</i>. 2020;105(12):dgaa635. doi:10.1210/clinem/dgaa635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/32901267/pubmed" id="32901267" target="_blank">32901267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17849739">
<a name="17849739"></a>Lomenick JP, Smith WJ. Low-dose adrenocorticotropic hormone stimulation testing in term infants. <i>J Pediatr Endocrinol Metab</i>. 2007;20(7):773-779.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/17849739/pubmed" id="17849739" target="_blank">17849739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20977425">
<a name="20977425"></a>Lunghi L, Pavan B, Biondi C, et al, "Use of Glucocorticoids in Pregnancy,"<i> Curr Pharm Des</i>, 2010, 16(32):3616-37.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/20977425/pubmed" id="20977425" target="_blank">20977425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21985166">
<a name="21985166"></a>Makol A, Wright K, and Amin S, "Rheumatoid Arthritis and Pregnancy: Safety Considerations in Pharmacological Management," <i>Drugs</i>, 2011, 71(15):1973-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/21985166/pubmed" id="21985166" target="_blank">21985166</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19136406">
<a name="19136406"></a>Marik PE, “Critical Illness-Related Corticosteroid Insufficiency,” <i>Chest</i>, 2009, 135(1):181-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/19136406/pubmed" id="19136406" target="_blank">19136406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18496365">
<a name="18496365"></a>Marik PE, Pastores SM, Annane D, et al, "Recommendations for the Diagnosis and Management of Corticosteroid Insufficiency in Critically Ill Adult Patients: Consensus Statements From an International Task Force by the American College of Critical Care Medicine," <i>Crit Care Med</i>, 2008, 36(6):1937-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/18496365/pubmed" id="18496365" target="_blank">18496365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19506586">
<a name="19506586"></a>Østensen M and Forger F, "Management of RA Medications in Pregnant Patients," <i>Nat Rev Rheumatol</i>, 2009, 5(7):382-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/19506586/pubmed" id="19506586" target="_blank">19506586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11091360">
<a name="11091360"></a>Park-Wyllie L, Mazzotta P, Pastuszak A, et al, "Birth defects After Maternal Exposure to Corticosteroids: Prospective Cohort Study and Meta-Analysis of Epidemiological Studies," <i>Teratology</i>, 2000, 62(6):385-92.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/11091360/pubmed" id="11091360" target="_blank">11091360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14745915">
<a name="14745915"></a>Pradat P, Robert-Gnansia E, Di Tanna GL, et al, “First Trimester Exposure to Corticosteroids and Oral Clefts,” <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(12):968-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/14745915/pubmed" id="14745915" target="_blank">14745915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25901540">
<a name="25901540"></a>Robert SM, Borasino S, Dabal RJ, Cleveland DC, Hock KM, Alten JA. Postoperative hydrocortisone infusion reduces the prevalence of low cardiac output syndrome after neonatal cardiopulmonary bypass.<i> Pediatr Crit Care Med</i>. 2015;16(7):629-636.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/25901540/pubmed" id="25901540" target="_blank">25901540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10681636">
<a name="10681636"></a>Rose SR, Lustig RH, Burstein S, Pitukcheewanont P, Broome DC, Burghen GA. Diagnosis of ACTH deficiency. Comparison of overnight metyrapone test to either low-dose or high-dose ACTH test. <i>Horm Res</i>. 1999;52(2):73-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/10681636/pubmed" id="10681636" target="_blank">10681636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16508586">
<a name="16508586"></a>Rossi GP, Ganzaroli C, Miotto D, et al. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. <i>J Hypertens</i>. 2006;24(2):371-379.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/16508586/pubmed" id="16508586" target="_blank">16508586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18398342">
<a name="18398342"></a>Rossi GP, Pitter G, Bernante P, Motta R, Feltrin G, Miotto D. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. <i>J Hypertens</i>. 2008;26(5):989-997. doi: 10.1097/HJH.0b013e3282f9e66a.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/18398342/pubmed" id="18398342" target="_blank">18398342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29687091">
<a name="29687091"></a>Shibayama Y, Wada N, Naruse M, et al. The occurrence of apparent bilateral aldosterone suppression in adrenal vein sampling for primary aldosteronism. <i>J Endocr Soc</i>. 2018;2(5):398-407. doi: 10.1210/js.2017-00481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/29687091/pubmed" id="29687091" target="_blank">29687091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30272171">
<a name="30272171"></a>Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(11):4043-4088. doi:10.1210/jc.2018-01865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/30272171/pubmed" id="30272171" target="_blank">30272171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20823466">
<a name="20823466"></a>Speiser PW, Azziz R, Baskin LS, et al, "Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline," <i>J Clin Endocrinol Metab</i>, 2010, 95(9):4133-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/20823466/pubmed" id="20823466" target="_blank">20823466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18184957">
<a name="18184957"></a>Sprung CL, Annane D, Keh D, et al, “Hydrocortisone Therapy for Patients With Septic Shock,” <i>N Engl J Med</i>, 2008, 358(2):111-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/18184957/pubmed" id="18184957" target="_blank">18184957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Synacthen.1">
<a name="Synacthen.1"></a>Synacthen Depot (cosyntropin) [product monograph]. Kirkland, Quebec, Canada: Valeo Pharma Inc; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9709938">
<a name="9709938"></a>Thaler LM and Blevins LS, “The Low Dose (1-μg) Adrenocorticotropin Stimulation Test in the Evaluation of Patients With Suspected Central Adrenal Insufficiency,” <i>J Clin Endocrinol Metab</i>, 1998, 83(8):2726-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/9709938/pubmed" id="9709938" target="_blank">9709938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7714104">
<a name="7714104"></a>Tordjman K, Jaffe A, Grazas N, et al, “The Role of the Low Dose (1 microgram) Adrenocorticotropin Test in the Evaluation of Patients With Pituitary Diseases,” <i>J Clin Endocrinol Metab</i>, 1995, 80(4):1301-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/7714104/pubmed" id="7714104" target="_blank">7714104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16159938">
<a name="16159938"></a>Watterberg KL, Shaffer ML, Garland JS, et al, "Effect of Dose on Response to Adrenocorticotropin in Extremely Low Birth Weight Infants," <i>J Clin Endocrinol Metab</i>, 2005, 90(12):6380-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/16159938/pubmed" id="16159938" target="_blank">16159938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15657580">
<a name="15657580"></a>Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. <i>Surgery</i>. 2004;136(6):1227-1235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cosyntropin-tetracosactide-pediatric-drug-information/abstract-text/15657580/pubmed" id="15657580" target="_blank">15657580</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13183 Version 172.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
